Regulatory Decision on Class of Alzheimer’s Drugs Has the Potential to Deny the Minority Community Access to Treatment
April 7, 2022
Late last spring, the FDA approved the first new Alzheimer’s disease therapy since 2003. For the six million plus U.S. citizens living with this fatal disease, approval of a medicine designed to treat the underlying cause of the disease was a breakthrough.